Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT4 | P35916 | 4/20 | 0.41 |
| ▸ | BRAF | P15056 | 5/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 4/20 | 0.38 |
| ▸ | ITK | Q08881 | 2/20 | 0.38 |
| ▸ | NPR3 | P17342 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15524717 | 0.91 | FLT4 (0.44) | FLT4BRAFMAPK1RPS6KA1ACACB | |
| SCHEMBL15524495 | 0.89 | FLT4 (0.48) | FLT4 | |
| SCHEMBL15524831 | 0.85 | EGFR (0.46) | EGFRITKBTK | |
| SCHEMBL15513626 | 0.84 | FLT4 (0.46) | FLT4BRAFMAPK1RPS6KA1ACACB | |
| SCHEMBL15524534 | 0.81 | FLT4 (0.57) | FLT4BRAFNPR3 | |
| SCHEMBL15524487 | 0.80 | STAT6 (0.44) | EGFRITKSYK | |
| SCHEMBL15524302 | 0.80 | IGF1R (0.44) | MAPK1EGFRNPR3BTKMEN1 | |
| SCHEMBL15524121 | 0.80 | SYK (0.51) | SYK | |
| SCHEMBL15524392 | 0.78 | STAT6 (0.50) | FLT4BTKSYK | |
| SCHEMBL15513711 | 0.77 | FLT4 (0.49) | FLT4BRAFMAPK1RPS6KA1NPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | FLT4 1/4885BRAF 166/4885MAPK1 185/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | FLT4 1/4885BRAF 117/4885MAPK1 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.